1. Home
  2. |Insights
  3. |PODCAST: President Trump’s Early Trade Policy Moves – What it Means for Business — C&M’s First 100 Days Series

PODCAST: President Trump’s Early Trade Policy Moves – What it Means for Business — C&M’s First 100 Days Series

Client Alert | 1 min read | 02.03.17

As part of Crowell & Moring’s “First 100 Days” series, Paul Davies and Andrew Blasi of C&M International, Crowell & Moring’s international policy and regulatory affairs consulting affiliate, discuss the trade policy moves made so far by the Trump Administration, and what it means for businesses who are involved in trade issues. Paul is a director at C&M International and a former Australian trade negotiator. Andrew is an associate director at C&M International and a former staff member of the US-ASEAN Business Council and the U.S. House of Representatives.

Covered in this 16 minute podcast:

  • President Trump’s early trade policy emphasis on limiting imports and eliminating the trade deficit.
  • Implications of the U.S. withdrawal from TPP and the main takeaways for businesses.
  • The president’s upcoming meeting with Prime Minister Abe of Japan and where things stand.
  • Thoughts on NAFTA and what businesses might expect.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...